Iceland· IS-EU/1/14/934/001
Plegridy
A peginterferon beta-1a product containing peginterferonum beta-1a inn, registered in Iceland by Biogen Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Peginterferon beta-1a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB13 (peginterferon beta-1a), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Peginterferon beta-1a · ATC L03AB13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of peginterferon beta-1a costs, country by country.
Normalised to the WHO defined daily dose (8.9 mcg), the median price runs from $1.58 in Czechia to $45.18 in Switzerland — a ×29 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Peginterferon beta-1a · price per daily dose (8.9 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$45.18
- CZ Czechia$1.58
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Peginterferonum beta-1a INN
- Manufacturer
- Biogen Netherlands B.V.
- Country
- Iceland (IS)
- ATC code
- L03AB13
- ATC class
- Peginterferon beta-1a
- Defined daily dose
- 8.9 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
338 interactions on record for peginterferon beta-1a.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Peginterferon beta-1a · interactions on record
338 records
- 15 severe
- 323 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- ClotrimazoleA01AB18moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Peginterferon beta-1a in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPLEGRIDYBiogen Netherlands B.V., Badhoevedorp
- United StatesPlegridyBiogen Inc.
- United KingdomPlegridy 125micrograms/0.5ml solution for injection pre-filled pensBiogen Idec Ltd
- SpainPLEGRIDY 125 microgramos SOLUCION INYECTABLE EN JERINGA PRECARGADA IMBiogen Netherlands B.V.
- FinlandPlegridyBiogen Netherlands B.V.
- BelgiumPlegridy 125 µgBiogen Netherlands
- ItalyPLEGRIDY*1 penna SC 63 mcg 0,5 ml + 1 penna 94 mcg 0,5 mlBIOGEN NETHERLANDS B.V.
- FrancePLEGRIDY 125 microgrammes, solution injectable en seringue préremplieBIOGEN NETHERLANDS (PAYS-BAS)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Plegridy
- Norway · Plegridy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9da17ad6-99c8-4a30-8f91-2b81dbb5f2cb GET /v1/drugs/9da17ad6-99c8-4a30-8f91-2b81dbb5f2cb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "L03AB13",
"marketed": true,
"strength": "63 míkróg + 94 míkróg",
"ma_number": "EU/1/14/934/001",
"substance": "Peginterferonum beta-1a INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í taugasjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "41838"
}See everything about peginterferon beta-1a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.